Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s

Link to article at PubMed

Chest. 2020 Oct 16:S0012-3692(20)34902-3. doi: 10.1016/j.chest.2020.10.011. Online ahead of print.


OBJECTIVE: Pulmonary disease is a potentially serious yet underdiagnosed complication of Sjögren's syndrome, the second most common autoimmune rheumatic disease. Approximately 16% of patients with Sjögren's demonstrate pulmonary involvement with higher mortality and lower quality of life. Clinical practice guidelines for pulmonary manifestations of Sjögren's were developed by the Sjögren's Foundation after identifying a critical need for early diagnosis and improved quality and consistency of care.

METHODS: A rigorous and transparent methodology was followed according to American College of Rheumatology (ACR) guidelines. The Pulmonary Topic Review Group (TRG) developed clinical questions in the PICO (Patient, Intervention, Comparison, Outcome) format and selected literature search parameters. Each article was reviewed by a minimum of two TRG members for eligibility and assessment of quality of evidence and strength of recommendation. Guidelines were then drafted based on available evidence, expert opinion, and clinical importance. Draft recommendations with a clinical rationale and data extraction tables were submitted to a Consensus Expert Panel (CEP) for consideration and approval, with at least 75% agreement required for individual recommendations to be included in the final version.

RESULTS: The literature search revealed 1,192 articles, of which 150 qualified for consideration in guideline development. Of the original 85 PICO questions posed by the TRG, 51 recommendations were generated. These were then reviewed by the CEP and 51 recommendations were finalized, with a mean agreement of 97.71% (range 79-100%). The recommendations span topics of evaluating Sjögren's patients for pulmonary manifestations and assessing, managing and treating upper and lower airway disease, interstitial lung disease, and lymphoproliferative disease.

CONCLUSION: Clinical practice guidelines for pulmonary manifestations in Sjögren's will improve early identification, evaluation, and uniformity of care by primary care physicians, rheumatologists and pulmonologists. Additionally, opportunities for future research are identified.

PMID:33075377 | DOI:10.1016/j.chest.2020.10.011

Leave a Reply

Your email address will not be published. Required fields are marked *